ReviewAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology2023
Secondary immunodeficiencies and infectious considerations of biologic immunomodulatory therapies.
Review in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- Therapeutic effects of Lentinan in gastrointestinal inflammation and carcinogenesis - A scoping review of evidence from preclinical and clinical studies.European journal of microbiology & immunology · 2026Review
- Burden of Invasive Meningococcal Disease: Evolving Epidemiology and Implications for Prevention Policy.Infectious diseases and therapy · 2026Review
- Utility of mouse precision cut lung slices as an in vitro model for interrogating the lung immune response against bacterial pathogens in the context of immunomodulatory therapeutics.Respiratory research · 2026Article
- Infectious Risks Associated with Biologic Therapies in Autoimmune, Rheumatologic and Dermatologic Diseases: A Narrative Review.Microorganisms · 2026Review
- [Clinical profile of patients with secondary immunodeficiency on immunoglobulin replacement therapy].Revista medica del Instituto Mexicano del Seguro Social · 2026Observational
- Steroid receptor coactivators in immunity - From function to emerging translational opportunities.The Journal of biological chemistry · 2026Review
- Infectious adverse events in patients treated with biotherapies in a tropical Amazonian context, French Guiana.BMC infectious diseases · 2026Article
- Real-world safety of satralizumab in neuromyelitis optica spectrum disorder: a FAERS-based risk stratification study.Journal of neurology · 2026Article
- Serious Infection Risk with Systemic Treatments for Psoriasis: A Systematic Review and Network Meta-analysis Combining Randomised and Non-randomised Evidence.Dermatology and therapy · 2026Review
- The human skin microbiome: from metagenomes to therapeutics.Nature reviews. Microbiology · 2025Review
- Safety and tolerability of astegolimab, an anti-ST2 monoclonal antibody: a narrative review.Respiratory research · 2025Review
- Immunodeficiencies in Adults: Key Considerations for Diagnosis and Management.Clinical reviews in allergy & immunology · 2025Review
- Liver-targeted allergen immunotherapy rapidly and safely induces antigen-specific tolerance to treat allergic airway disease in mice.Science translational medicine · 2025Article
- Unveiling Psoriasis: Delving into Pathogenesis, Treatment Breakthroughs, and Patent Trends.Recent advances in inflammation & allergy drug discovery · 2025Review
- Infectious Diseases and Secondary Antibody Deficiency in Patients from a Mesoregion of São Paulo State, Brazil.Tropical medicine and infectious disease · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Biologic immunomodulatory medications have rapidly expanded in the previous decades, providing new treatment options for individuals with a spectrum of oncologic, allergic, rheumatologic, and neurologic conditions. Biologic therapies alter immune function and can impair key host defense mechanisms, resulting in secondary immunodeficiency and increased infectious risks. Biologic medications can increase general risk for upper respiratory tract infections but can also be associated with unique infectious risks owing to distinct mechanisms of action. With the widespread use of these medications, providers in every area of medicine will likely care for individuals receiving biologic therapies and understanding their potential infectious complications can help mitigate these risks. This practical review discusses the infectious implications of biologics by class of medication and provides recommendations regarding the examination and screening both before therapy initiation and while the patient is receiving the medication. With this knowledge and background, providers can reduce risk whereas patients receive the treatment benefits of these biologic medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.